Heart hope: HIV-positive women may get better blood flow with common diabetes pills

NCT ID NCT06843902

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether SGLT2 inhibitors, a class of diabetes and kidney drugs, can improve blood flow through the heart's small arteries in women with HIV who also have diabetes or chronic kidney disease. Eighty women aged 45-75 will be randomly assigned to health education alone or health education plus a referral to a specialist who may prescribe an SGLT2 inhibitor. The goal is to see if the drug helps prevent heart attacks by improving coronary blood flow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SGLT2 inhibitors (e.g., empagliflozin or dapagliflozin)
What this could lead to
If successful, this could show that SGLT2 inhibitors improve blood flow in the heart's small arteries, potentially reducing heart attack risk in women with HIV.
What could go wrong
This is a small, early-phase trial with only 80 participants. It tests a secondary effect of an already-approved drug, so the heart benefit may not be confirmed. The study also relies on doctors prescribing the drug, which may not happen for all participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.